Literature DB >> 20439715

Hepatitis B virus core antigen determines viral persistence in a C57BL/6 mouse model.

Yi-Jiun Lin1, Li-Rung Huang, Hung-Chih Yang, Horng-Tay Tzeng, Ping-Ning Hsu, Hui-Lin Wu, Pei-Jer Chen, Ding-Shinn Chen.   

Abstract

We recently developed a mouse model of hepatitis B virus (HBV) persistence, in which a single i.v. hydrodynamic injection of HBV DNA to C57BL/6 mice allows HBV replication and induces a partial immune response, so that about 20-30% of the mice carry HBV for more than 6 months. The model was used to identify the viral antigen crucial for HBV persistence. We knocked out individual HBV genes by introducing a premature termination codon to the HBV core, HBeAg, HBx, and polymerase ORFs. The specific-gene-deficient HBV mutants were hydrodynamically injected into mice and the HBV profiles of the mice were monitored. About 90% of the mice that received the HBcAg-mutated HBV plasmid exhibited high levels of hepatitis B surface antigenemia and maintained HBsAg expression for more than 6 months after injection. To map the region of HBcAg essential for viral clearance, we constructed a set of serial HBcAg deletion mutants for hydrodynamic injection. We localized the essential region of HBcAg to the carboxyl terminus, specifically to the 10 terminal amino acids (HBcAg176-185). The majority of mice receiving this HBV mutant DNA did not elicit a proper HBcAg-specific IFN-gamma response and expressed HBV virions for 6 months. These results indicate that the immune response triggered in mice by HBcAg during exposure to HBV is important in determining HBV persistence.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20439715      PMCID: PMC2889105          DOI: 10.1073/pnas.1004762107

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  26 in total

1.  The arginine-rich carboxy-terminal domain of the hepatitis B virus core protein mediates attachment of nucleocapsids to cell-surface-expressed heparan sulfate.

Authors:  Peter Vanlandschoot; Freya Van Houtte; Benedikte Serruys; Geert Leroux-Roels
Journal:  J Gen Virol       Date:  2005-01       Impact factor: 3.891

2.  Interaction of the hepatitis B core antigen and the innate immune system.

Authors:  Byung O Lee; Amy Tucker; Lars Frelin; Matti Sallberg; Joyce Jones; Cory Peters; Janice Hughes; David Whitacre; Bryan Darsow; Darrell L Peterson; David R Milich
Journal:  J Immunol       Date:  2009-06-01       Impact factor: 5.422

3.  Exposure of RNA templates and encapsidation of spliced viral RNA are influenced by the arginine-rich domain of human hepatitis B virus core antigen (HBcAg 165-173).

Authors:  Sophie Le Pogam; Pong Kian Chua; Margaret Newman; Chiaho Shih
Journal:  J Virol       Date:  2005-02       Impact factor: 5.103

4.  Enhancement of hepatitis B virus replication by the regulatory X protein in vitro and in vivo.

Authors:  Victor V Keasler; Amanda J Hodgson; Charles R Madden; Betty L Slagle
Journal:  J Virol       Date:  2006-12-20       Impact factor: 5.103

5.  The hepatitis B virus X protein transactivates viral core gene expression in vivo.

Authors:  K Reifenberg; H Wilts; J Löhler; P Nusser; R Hanano; L G Guidotti; F V Chisari; H J Schlicht
Journal:  J Virol       Date:  1999-12       Impact factor: 5.103

6.  Role of B cells in antigen presentation of the hepatitis B core.

Authors:  D R Milich; M Chen; F Schödel; D L Peterson; J E Jones; J L Hughes
Journal:  Proc Natl Acad Sci U S A       Date:  1997-12-23       Impact factor: 11.205

7.  Immune tolerance split between hepatitis B virus precore and core proteins.

Authors:  Margaret Chen; Matti Sällberg; Janice Hughes; Joyce Jones; Luca G Guidotti; Francis V Chisari; Jean-Noel Billaud; David R Milich
Journal:  J Virol       Date:  2005-03       Impact factor: 5.103

8.  Resolution of chronic hepatitis B and anti-HBs seroconversion in humans by adoptive transfer of immunity to hepatitis B core antigen.

Authors:  George K K Lau; Deepak Suri; Raymond Liang; Eirini I Rigopoulou; Mark G Thomas; Ivana Mullerova; Amin Nanji; Siu-Tsan Yuen; Roger Williams; Nikolai V Naoumov
Journal:  Gastroenterology       Date:  2002-03       Impact factor: 22.682

9.  An immunocompetent mouse model for the tolerance of human chronic hepatitis B virus infection.

Authors:  Li-Rung Huang; Hui-Lin Wu; Pei-Jer Chen; Ding-Shinn Chen
Journal:  Proc Natl Acad Sci U S A       Date:  2006-11-09       Impact factor: 11.205

10.  RNA interference-mediated control of hepatitis B virus and emergence of resistant mutant.

Authors:  Hui-Lin Wu; Li-Rung Huang; Chuan-Chuan Huang; Hsiao-Lei Lai; Chun-Jen Liu; Yu-Tzu Huang; Yun-Wei Hsu; Cheng-Yi Lu; Ding-Shinn Chen; Pei-Jer Chen
Journal:  Gastroenterology       Date:  2005-03       Impact factor: 22.682

View more
  36 in total

1.  Tumor necrosis factor-alpha blockage therapy impairs hepatitis B viral clearance and enhances T-cell exhaustion in a mouse model.

Authors:  I-Tsu Chyuan; Hwei-Fang Tsai; Horng-Tay Tzeng; Chi-Chang Sung; Chien-Sheng Wu; Pei-Jer Chen; Ping-Ning Hsu
Journal:  Cell Mol Immunol       Date:  2015-02-09       Impact factor: 11.530

2.  Eliminating hepatitis B by antagonizing cellular inhibitors of apoptosis.

Authors:  Gregor Ebert; Cody Allison; Simon Preston; James Cooney; Jesse G Toe; Michael D Stutz; Samar Ojaimi; Nikola Baschuk; Ueli Nachbur; Joseph Torresi; John Silke; C Glenn Begley; Marc Pellegrini
Journal:  Proc Natl Acad Sci U S A       Date:  2015-04-20       Impact factor: 11.205

Review 3.  Precore/core region mutations of hepatitis B virus related to clinical severity.

Authors:  Hong Kim; Seoung-Ae Lee; Seung Yeon Do; Bum-Joon Kim
Journal:  World J Gastroenterol       Date:  2016-05-07       Impact factor: 5.742

4.  Maternal-Derived Hepatitis B Virus e Antigen Alters Macrophage Function in Offspring to Drive Viral Persistence after Vertical Transmission.

Authors:  Yongjun Tian; Cheng-Fu Kuo; Omid Akbari; Jing-Hsiung James Ou
Journal:  Immunity       Date:  2016-05-03       Impact factor: 31.745

Review 5.  Experimental models and therapeutic approaches for HBV.

Authors:  Maura Dandri; Marc Lütgehetmann; Jörg Petersen
Journal:  Semin Immunopathol       Date:  2012-08-17       Impact factor: 9.623

6.  Hepatitis B virus nucleocapsid but not free core antigen controls viral clearance in mice.

Authors:  Yi-Jiun Lin; Hui-Lin Wu; Ding-Shinn Chen; Pei-Jer Chen
Journal:  J Virol       Date:  2012-06-20       Impact factor: 5.103

7.  Hepatitis B virus core protein sensitizes hepatocytes to tumor necrosis factor-induced apoptosis by suppression of the phosphorylation of mitogen-activated protein kinase kinase 7.

Authors:  Baosen Jia; Minggao Guo; Gaiyun Li; Demin Yu; Xinxin Zhang; Ke Lan; Qiang Deng
Journal:  J Virol       Date:  2014-11-26       Impact factor: 5.103

8.  Hepatitis B Virus Surface Antigen Enhances the Sensitivity of Hepatocytes to Fas-Mediated Apoptosis via Suppression of AKT Phosphorylation.

Authors:  Zhen-Tang Jing; Wei Liu; Shu-Xiang Wu; Yun He; Yan-Ting Lin; Wan-Nan Chen; Xin-Jian Lin; Xu Lin
Journal:  J Immunol       Date:  2018-08-31       Impact factor: 5.422

9.  Synthetic DNA immunogen encoding hepatitis B core antigen drives immune response in liver.

Authors:  N Obeng-Adjei; D K Choo; J Saini; J Yan; P Pankhong; A Parikh; J S Chu; D B Weiner
Journal:  Cancer Gene Ther       Date:  2012-10-05       Impact factor: 5.987

10.  Hepatitis B Virus X Protein Induces Hepatic Steatosis by Enhancing the Expression of Liver Fatty Acid Binding Protein.

Authors:  Yun-Li Wu; Xian-E Peng; Yi-Bing Zhu; Xiao-Li Yan; Wan-Nan Chen; Xu Lin
Journal:  J Virol       Date:  2015-12-04       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.